Other MAP-K Pathway Driven Diseases
1 clinical trials · Condition
◉ Watch Other MAP-K Pathway Driven Diseases
| Record | Firm | Date |
|---|---|---|
| Individual Patient Compassionate Use of Mirdametinib (NCT05028166) | SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany |
Track Other MAP-K Pathway Driven Diseases automatically
Every clearance here is in the API, with alerts when new ones post.